 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Long-term follow-up results of the Phase 3 coBRIM study of Verofenib + Pabocinil in the treatment of BRAFV600+ advanced melanoma

Clin Cancer Res: Long-term follow-up results of the Phase 3 coBRIM study of Verofenib + Pabocinil in the treatment of BRAFV600+ advanced melanoma

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

ttf 1 positive

cilacar 5 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Vemurafenib (Vemurafenib) is a kinase inhibitor that inhibits BRAF (serine-threonine kinase) to prevent the proliferation of cells lacking cytokines, thereby playing an anti-tumor effect
.

Verofenib was approved for marketing in the United States in 2011.

The randomized phase 3 coBRIM study (NCT01689519) confirmed that in patients with BRAF V600 mutation-positive advanced melanoma who have not been treated before, compared with veirofenib alone, the combination of veirofenib and cobimetinib (Cobimetinib) Improve progression-free survival (PFS) and overall survival (OS)
.

This article reports the long-term follow-up results of the coBRIM study
.

In this study, the test patients were randomly divided into two groups 1:1, and received oral pabocinib (60 mg/day for 21 days, stop for 7 days) or placebo combined with oral veirofenib (960 mg, 2/day)
.

OS of the two groups of patients in the entire study cohort

A total of 495 patients were randomly assigned to the Pabocinil + Verofenib group (n=247) or Verofenib group (n=248)
.

At a median follow-up of 21.

OS in patients stratified by baseline lactate dehydrogenase level

Patients with normal baseline lactate dehydrogenase levels and low tumor burden and patients with complete remission had the longest OS and PFS
.

The safety is consistent with previous reports

Patients with normal baseline lactate dehydrogenase levels and low tumor burden and patients with complete remission had the longest OS and PFS

In summary, the results of the extended follow-up of the coBRIM study confirmed that compared with veilofenib alone, veilofenib combined with pabocinib can bring long-term clinical benefits to patients with advanced melanoma who are BRAF V600 mutation-positive
.

Compared with veirofenib alone, veirofenib combined with pabocinib can bring long-term clinical benefits to patients with BRAF V600 mutation-positive advanced melanoma
.

Compared with veirofenib alone, veirofenib combined with pabocinib can bring long-term clinical benefits to patients with BRAF V600 mutation-positive advanced melanoma

Original source:

Paolo A.

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.